MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from stock
offerings, net of issuance...
$567,115K
Proceeds from stock
offerings, net of issuance...
$123,873K
Proceeds from exercise of
options and employee...
$13,274K
Net cash provided by
financing activities
$702,173K
Canceled cashflow
$2,089K
Increase in cash, cash
equivalents and restricted...
$141,957K
Canceled cashflow
$560,216K
Payments of tax
withholdings related to...
$2,089K
Maturities of marketable
securities
$312,720K
Stock-based compensation
expense
$33,941K
Accounts payable
$12,097K
Accrued expenses
$11,200K
Non-cash operating lease
expense
$1,040K
Prepaid expenses and
other current assets
-$640K
Depreciation expense
$140K
Net cash (used in)
provided by investing...
-$311,148K
Net cash used in
operating activities
-$249,068K
Canceled cashflow
$312,720K
Canceled cashflow
$59,058K
Other income, net
$22,930K
Purchases of marketable
securities
$623,812K
Net loss
-$303,268K
Purchases of property and
equipment
$56K
Canceled cashflow
$22,930K
Amortization of premiums and
discounts on marketable...
$3,592K
Operating lease
liabilities
-$1,259K
Other non-cash
adjustments
$7K
Program-specific
expenses-Vormatrigine
$74,059K
Personnel-related expenses
$64,719K
Program-specific
expenses-Ulixacaltamide
$63,207K
Program-specific
expenses-Relutrigine
$45,951K
Stock-based compensation
expense
$33,941K
Other segment
expenses
$29,329K
Program-specific expenses-Other
Early State Assets
$8,019K
Program-specific
expenses-Elsunersen
$6,833K
Depreciation expense
$140K
Back
Back
Cash Flow
source: myfinsight.com
Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines, Inc. (PRAX)